AstraZeneca’s blood thinner Brilinta posted dismal results in a large clinical study pitting the heart drug against aspirin in preventing recurrent heart attacks in the 90 days following a stroke. The benefit was so slight that researchers didn’t think it statistically significant, crushing the drug company’s hopes of racking up annual sales of $3.5 billion by 2023. AstraZeneca is also testing the drug in patients with peripheral artery disease, and hopes to have that data later this year. Brilinta is known as an anti-platelet, which prevents blood clots by preventing platelets in the blood from sticking together. It is used ... Read More
Righting Injustice is published by the Beasley Allen Law Firm. If you are interested in a free legal consultation, please take a few moments to fill out the contact form with as many details as possible. The more information you provide us, the better we can evaluate your claim.